凱萊英(06821.HK)：上海凱萊英生物技術獲增資25.34億元 高瓴實體獲授認購期權可追加收購不超共2%股權
格隆匯3月25日丨凱萊英(06821.HK)公吿，於2022年3月25日，公司、凱萊英生物技術及目標公司上海凱萊英生物技術發展有限公司與投資者訂立增資協議，據此，公司及投資者同意向目標公司股本增資，總額最高約為人民幣25.34億元。
於本公吿日期，目標公司為公司全資附屬公司。視作出售事項完成後，目標公司將(i)分別由投資者合共擁有約17%的權益及公司擁有約83%的權益（假設認購期權未獲行使）；或(ii)分別由投資者合共擁有約18.84%的權益及公司擁有約81.16%的權益（假設認購期權獲悉數行使），故目標公司仍為公司非全資附屬公司。
根據增資協議，高瓴實體獲授權利以自行酌情(i)於第一輪截止日期後一年內以代價約人民幣4494萬元，追加收購目標公司1.00%的股權（認購期權(i)）；及(ii)於第一輪截止日期後兩年內以代價約人民幣7954.5萬元，追加收購目標公司1.00%的股權（認購期權(ii)）。
目標公司乃於2022年3月23日就增資協議項下交易而新成立，且分別於截至2020年12月31日及2021年12月31日止年度並無歷史財務記錄。凱萊英生物技術於本公吿日期為公司全資附屬公司，根據增資協議將於第一輪截止日期或之前成為目標公司的全資附屬公司。
凱萊英生物技術為一間於中國註冊成立的有限責任公司，於本公吿日期乃公司的全資附屬公司，並將根據增資協議於第一輪截止日期或之前成為目標公司的全資附屬公司。凱萊英生物技術為生物製品及先進療法的CDMO領域的全球領先企業，提供大分子藥物、抗體偶聯藥物、細胞基因治療藥物及mRNA藥物。
透過訂立增資協議，公司將能夠通過增資擴股方式引入外部投資者，棧稃合公司未來發展戰略。本次增資有利於增強公司的財務實力，滿足公司後續資本支出和經營支出的資金需求，提升公司的整體競爭力並促進公司CDMO業務的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
